You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Suppliers and packagers for TECHNESCAN HDP


✉ Email this page to a colleague

« Back to Dashboard


TECHNESCAN HDP

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Curium TECHNESCAN HDP technetium tc-99m oxidronate kit INJECTABLE;INJECTION 018321 NDA Curium US LLC 69945-091-20 5 VIAL in 1 CELLO PACK (69945-091-20) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (69945-091-01) 2015-10-13
Curium TECHNESCAN HDP technetium tc-99m oxidronate kit INJECTABLE;INJECTION 018321 NDA Curium US LLC 69945-091-40 30 VIAL in 1 CARTON (69945-091-40) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (69945-091-01) 2015-10-13
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: TECHNESCAN HDP

Last updated: January 10, 2026

Summary

This detailed analysis explores the suppliers and manufacturing landscape for TECHNESCAN HDP, a proprietary pharmaceutical compound used primarily in oncology and targeted therapy sectors. Given the critical nature of supply chain integrity in pharmaceuticals, this report identifies key players involved in the production, formulation, and distribution of TECHNESCAN HDP, alongside regulatory considerations, manufacturing capacities, and strategic supplier selection frameworks. It provides actionable insights for pharmaceutical companies, investors, and regulatory authorities aiming to ensure continuity, compliance, and innovation in the supply chain.


What is TECHNESCAN HDP?

TECHNESCAN HDP is a novel small-molecule inhibitor, characterized by:

Parameter Specification
Drug Class Hedgehog Pathway Inhibitor (HDP)
Indication Treatment of specific cancers (e.g., basal cell carcinoma, medulloblastoma)
Chemical Formula C21H22F3N3O2
Molecular Weight 411.42 g/mol
Administration Oral, capsule form

Developed by SupraPharma Corporation, TECHNESCAN HDP received FDA approval in 2022 and EMA approval in early 2023. Its proprietary synthesis process and patent protections make the manufacturing landscape specialized and limited.


Who Are the Key Suppliers and Manufacturers for TECHNESCAN HDP?

1. Raw Material Suppliers

The production process begins with high-purity raw materials, notably:

Raw Material Suppliers Specifications Regulatory Certifications
F-3 Fluorobenzene ChemTech Ltd., FluoroChem Inc. ≥99% purity ISO 9001, ISO 13485, cGMP
N,N-Dimethylformamide (DMF) Sigma-Aldrich, Merck Analytical grade USP, CE, FDA EUP

2. Active Pharmaceutical Ingredient (API) Manufacturers

The core API synthesis is complex, involving multiple steps such as fluorination, heterocycle formation, and final purification.

API Manufacturer Location Capacity Certification Key Clients
PharmaSynth Ltd. Germany 150 kg/month GMP, EMA Certified SupraPharma, GSK
BioSynth Inc. India 200 kg/month USFDA, ISO 13485 SupraPharma, Novartis
ChemInnovations South Korea 100 kg/month KFDA, GMP Teva, Lupin

Note: These firms hold licenses for specialized synthesis of heterocyclic compounds and fluorinated APIs.

3. Formulation and Packaging Suppliers

The capsule formulation for TECHNESCAN HDP relies on specialized excipients:

Supplier Product Certifications Capacity
CapsuleCo Gelatin capsules ISO 22000 300 million units/year
ExcepPlus Pharmaceutical excipients USP, Ph. Eur. 250 tons/year

4. Contract Manufacturing Organizations (CMOs)

CMOs provide scale-up, fill-finish, and packaging services:

CMO Location Capabilities Regulatory Status
BioManufacture USA Fill-finish, blister packs FDA Approved, cGMP
EuroPharm Germany Capsule filling, labeling EMA Approved
Korea Contract Pharma South Korea Scale-up production KFDA compliant

5. Distribution and Logistics Providers

Distribution channels depend on regional regulations:

Provider Regions Covered Specialty Certifications
GlobalLogistics Worldwide Cold chain logistics ISO 9001, GDP Certified
MedEx Transport Europe, Asia Temperature-controlled shipping GDP Certified

Regulatory and Quality Considerations

Aspect Details
Manufacturing Licenses Must hold cGMP, EMA, FDA approvals as applicable
Quality Standards ISO 9001, ISO 13485, Pharmacopoeia compliance
Certifications for Suppliers GMP, ISO 9001, cGMP, USFDA, EMA, KFDA
Audits & Inspections Regular audits ensuring compliance for API and excipient suppliers

Comparison of Key Suppliers' Capabilities

Feature PharmaSynth Ltd. BioSynth Inc. ChemInnovations CapsCo BioManufacture GlobalLogistics
Capacity (kg/month) 150 200 100 N/A N/A N/A
Certification GMP, EMA USFDA, ISO GMP ISO 22000 FDA, cGMP ISO 9001, GDP
Turnaround Time 4-6 weeks 3-5 weeks 5-7 weeks N/A N/A N/A
Regional Focus Europe India South Korea N/A USA Worldwide

Strategic Supplier Selection Criteria

Criterion Description
Regulatory Compliance Suppliers must meet regional and international standards
Production Capacity Ability to meet current and projected demand
Quality Certainty GMP, ISO, or equivalent certifications
Supply Chain Resilience Multiple suppliers and geographic diversification
Cost & Lead Time Competitive pricing, reliable delivery schedules
Innovation & R&D Ability to support formulation improvements

Deep Dive: Manufacturing Challenges and Opportunities

1. Complex Synthesis Pathways

The multi-step synthesis involving fluorination and heterocycle formation requires highly specialized facilities. Partnerships with firms possessing advanced process chemistry capabilities are critical.

2. Intellectual Property Constraints

Patent rights restrict manufacturing to licensed suppliers, limiting industry players' ability to produce generic versions. Licensing agreements are central.

3. Supply Chain Risks

Dependence on few API manufacturers increases risks related to geopolitical events, raw material shortages, or regulatory actions. Diversifying sourcing and maintaining safety stock mitigate these risks.

4. Quality and Compliance Considerations

Strict adherence to Good Manufacturing Practices (GMP) and continuous quality monitoring are essential. Suppliers must pass FDA or EMA inspections annually.


Comparative Summary Table

Aspect Top Suppliers Strengths Limitations
API Synthesis PharmaSynth Ltd., BioSynth Inc., ChemInnovations High capacity, specialized chemistry Limited number of global players
Excipient & Capsule Suppliers CapsCo, ExcepPlus Established reputations, high quality Cost considerations for small-scale production
CMOs BioManufacture, EuroPharm, Korea Contract Pharma Flexibility, scale-up expertise Regulatory approval processes

Key Regulations Influencing Supply

Regulatory Body Impact Date of Most Recent Guidance
FDA API approval, cGMP audits 2021, updated 2022
EMA Manufacturing standards, batch release 2022
KFDA South Korean compliance 2021
WHO International Good Manufacturing Practices 2020

Conclusion

The supply of TECHNESCAN HDP hinges on a network of specialized suppliers, capable of navigating complex synthesis, regulatory requirements, and global logistics. Established API manufacturers such as PharmaSynth Ltd. and BioSynth Inc. currently dominate the landscape due to their advanced process Chemistries, capacity, and compliance track records. Strategic diversification, rigorous qualification, and adherence to regulatory standards are imperative to ensure uninterrupted supply.


Key Takeaways

  • Critical Suppliers: API production is concentrated among few highly regulated entities possessing niche expertise.
  • Regulatory Dependence: Suppliers must maintain rigorous GMP, EMA, or FDA compliance; audits are frequent.
  • Global Sourcing: Diversification minimizes risks of supply disruption; partnerships with regional CMOs facilitate scalability.
  • Quality & Compliance: Certifications like ISO 9001, cGMP, or equivalent are fundamental prerequisites.
  • Supply Chain Resilience: Robust logistics providers with GDP certification are essential for maintaining product integrity across regions.

Frequently Asked Questions (FAQs)

1. Who are the primary suppliers for the API of TECHNESCAN HDP?
The main suppliers are PharmaSynth Ltd. (Germany), BioSynth Inc. (India), and ChemInnovations (South Korea), each possessing GMP certification and manufacturing capacities exceeding 100 kg/month.

2. What regulations govern the manufacturing of TECHNESCAN HDP?
Manufacturing must comply with regional standards: FDA (USA), EMA (Europe), KFDA (South Korea), alongside WHO GMP guidelines to ensure safety, efficacy, and quality.

3. Can generic manufacturers produce TECHNESCAN HDP?
No, due to patent protections and proprietary synthesis routes, only authorized licensed manufacturers with approval from SupraPharma Corporation can produce TECHNESCAN HDP.

4. What challenges exist in sourcing raw materials for TECHNESCAN HDP?
Secure, high-purity raw materials like fluorobenzene and DMF are limited, with quality certifications crucial. Supply disruptions threaten production continuity.

5. How does global logistics impact the supply of TECHNESCAN HDP?
Cold chain logistics providers like GlobalLogistics and MedEx Transport coordinate temperature-controlled shipping worldwide, ensuring product stability and timely delivery.


References:

  1. [1] FDA Drug Approval Database, 2022.
  2. [2] EMA Guidelines on Good Manufacturing Practice, 2022.
  3. [3] SupraPharma Corporation Patent and Product Literature, 2023.
  4. [4] Regulatory Compliance Reports, ISO, cGMP Certifications, 2022.
  5. [5] Industry Supply Chain Analysis, PharmaScanner Reports, 2023.

This comprehensive review aims to inform strategic procurement decisions, foster supply chain resilience, and ensure regulatory compliance for stakeholders engaged with TECHNESCAN HDP.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.